Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor TD-1473 showed a reduction in plasma exposure compared to?currently-approved JAK inhibitor. On June 9, 2016, Theravance Biopharma released positive results from a completed Phase I clinical trial of TD-1473, its oral GI-targeted pan-Janus kinase (JAK) inhibitor. TD-1473 is[…]
Kite Pharma granted access to PRIME regulatory support for KTE-C19 to treat chemorefractory DLBCL In a press release, Kite Pharma announced that it is?among first sponsors selected to participate in the EMAs enhanced regulatory program for investigational therapies that promise significant advances against serious diseases. ?The?European Medicines Agency (EMA) Committee for Medicinal Products for Human[…]
In Brief Biosimilar News reports that Sorrento’s experimental anti-IgE biosimilar, STI-004, met it’s primary endpoint in a 32-week, Phase 2/3 study conducted in China. ?Patients who received?STI-004 experienced?asthma exacerbation at a lower rate than those who received placebo: ?21% vs?55%. According to the Sorrento press release, the patient population included both?adult and adolescents suffering from[…]
Smart Bottle?Pharmacy Delivery Service According to a new report in Forbes, the start-up,?Circadian Design, has?innovated medication, vitamin, and refill reminders by combining a few old ideas. ?The new service is called?Round Refill?and?the reminders are generated?via a connection between a medication?bottle cap and?an app on your mobile.?? Pre-Ordering Available Business Wire is reporting that “Round[…]
Interviews by Marie Lux give great insights on patients: How they think and what they really want. #3sixtypharmaSME? ?What patients really want https://twitter.com/3SixtyPharma/status/734089140237656064